Drug class
Biguanides
Biguanides are a pharmacologic class of oral antihyperglycemic agents primarily indicated for the management of type 2 diabetes mellitus. Read more about Biguanides
149 drugs in this class 78 manufacturers
Drugs in Biguanides
GLYBURIDE-METFORMIN HCL (glyburide/metformin HCl)
JANUMET (sitagliptin phosphate/metformin HCl)
METFORMIN HCL
METFORMIN HCL
METFORMIN HCL
GLYBURIDE-METFORMIN HCL (glyburide/metformin HCl)
METFORMIN HCL ER (metformin HCl)
METFORMIN HCL ER (metformin HCl)
Biguanides are a pharmacologic class of oral antihyperglycemic agents primarily indicated for the management of type 2 diabetes mellitus.
They exert their therapeutic effects predominantly by reducing endogenous hepatic glucose production, decreasing intestinal glucose absorption, and enhancing peripheral insulin sensitivity to improve glucose uptake and utilization.
Metformin is the predominant agent of this class in modern clinical practice, serving as a foundational first-line therapy to improve glycemic control without stimulating insulin secretion or causing significant hypoglycemia.
-
fda.gov
Biguanides are a pharmacologic class of oral antihyperglycemic agents primarily indicated for the management of type 2 diabetes mellitus
-
fda.gov
Biguanides are a pharmacologic class of oral antihyperglycemic agents primarily indicated for the management of type 2 diabetes mellitus
-
fda.gov
They exert their therapeutic effects predominantly by reducing endogenous hepatic glucose production, decreasing intestinal glucose absorption, and enhancing peripheral insulin sensitivity to improve glucose uptake and utilization Metformin is the predominant agent of this class in modern clinical practice, serving as a foundational first-line therapy to improve glycemic control without stimulating insulin secretion or causing significant hypoglycemia
-
fda.gov
They exert their therapeutic effects predominantly by reducing endogenous hepatic glucose production, decreasing intestinal glucose absorption, and enhancing peripheral insulin sensitivity to improve glucose uptake and utilization
-
nih.gov
Metformin is the predominant agent of this class in modern clinical practice, serving as a foundational first-line therapy to improve glycemic control without stimulating insulin secretion or causing significant hypoglycemia
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.